文献速递冠心病血脂与心血管预防

慢性冠脉综合征双联抗栓治疗:ESC标准与CHADS-P2A2RC评分对比

Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究纳入61 338例首次行冠状动脉造影的慢性冠脉综合征患者,按2019 ESC指南标准和CHADS-P2A2RC评分进行风险分层。ESC标准识别33.9%为高风险,CHADS-P2A2RC评分识别24.9%为高风险。CHADS-P2A2RC评分可改善风险重分类,尤其有助于识别从治疗中获益有限低风险患者。

要点

  • 按2019 ESC指南,约三分之一CCS患者应考虑双联抗栓治疗。
  • CHADS-P2A2RC评分可正确向下重分类8%无事件患者,特异性提高9.7%。
  • CHADS-P2A2RC评分有助于识别双联抗栓治疗获益有限的低风险患者。

核心结论

  • 基于2019 ESC指南,约三分之一CCS患者应考虑双联抗栓治疗。
  • CHADS-P2A2RC评分改善风险分类,可能尤其识别出治疗获益有限的低风险患者。

研究设计与样本

  • 研究纳入2003-16年丹麦西部61 338例首次行冠状动脉造影的CCS患者。
  • 按2019 ESC指南标准和CHADS-P2A2RC评分对患者进行风险分层并比较。

主要发现

  • ESC标准识别33.9%为高风险、53.3%为中风险、12.8%为低风险。
  • CHADS-P2A2RC评分识别24.9%为高风险(≥4分)、48.1%为中风险(2-3分)、27.0%为低风险(≤1分)。
  • 两种方案均判为高风险者主要不良心血管事件为4.8/100人年(95%CI 4.6-5.0)。
  • ESC判高风险但CHADS-P2A2RC判低-中风险者事件率为2.1/100人年(95%CI 2.0-2.2)。
  • ESC判低-中风险但CHADS-P2A2RC判高风险者事件率为3.8/100人年(95%CI 3.6-4.1)。

关键数值与推荐

  • ESC标准将患者分为高风险33.9%、中风险53.3%、低风险12.8%。
  • CHADS-P2A2RC评分≥4分为高风险(24.9%),2-3分为中风险(48.1%),≤1分为低风险(27.0%)。

临床怎么用

  • 临床可依据2019 ESC指南标准识别约三分之一CCS患者考虑双联抗栓治疗。
  • CHADS-P2A2RC评分可辅助风险重分类,帮助识别双联抗栓治疗获益有限的低风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: According to the 2019 European Society of Cardiology (ESC) guidelines on chronic coronary syndromes (CCS), adding a P2Y12 inhibitor or rivaroxaban to aspirin should be considered in high-risk patients. We estimated the proportion of patients eligible for treatment with the ESC criteria and examined if a recently validated risk score (CHADS-P2A2RC) could improve risk prediction. METHODS AND RESULTS: We included 61 338 CCS patients undergoing first-time coronary angiography in Western Denmark (2003-16) and classified them according to the ESC criteria and the CHADS-P2A2RC score. The ESC criteria identified 33.9% as high risk, 53.3% as moderate risk, and 12.8% as low risk. The CHADS-P2A2RC score identified 24.9% as high risk (≥4 points), 48.1% as moderate risk (2-3 points), and 27.0% as low risk (≤1 points). Major adverse cardiovascular events per 100 person-years were 4.8 [95% confidence interval (CI) 4.6-5.0] in patients considered high risk with both schemes, 2.1 (95% CI 2.0-2.2) in patients considered high risk with the ESC but low-to-moderate risk with the CHADS-P2A2RC criteria, 3.8 (95% CI 3.6-4.1) in patients considered low-to-moderate risk with the ESC but high risk with the CHADS-P2A2RC criteria, and 1.5 (95% CI 1.5-1.6) in patients considered low-to-moderate risk with both schemes. The CHADS-P2A2RC score enabled correct downward risk reclassification of 5161 patients (8%) without events, yielding an improved specificity of 9.7%, a loss of sensitivity of 4.4%, and an overall net reclassification index of 0.053. CONCLUSION: Based on the 2019 ESC guidelines, dual antithrombotic treatment should be considered in one-third of CCS patients. The CHADS-P2A2RC score improved risk classification and may particularly identify low-risk patients with limited benefit from treatment.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Würtz M, Olesen KKW, Mortensen MB, et al. Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. Eur Heart J. 2022. PMID: 34871376. doi:10.1093/eurheartj/ehab785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。